THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...
The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy GoodRx (Nasdaq: GDRX), the leading platform for medication ...
Matthew Herper covers medical innovation — both its promise and its perils. Amgen said Thursday that its cholesterol-lowering shot, Repatha, prevented a composite of heart disease death, heart attack, ...
Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A cholesterol-lowering injection ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy “In a healthcare system where affordability too often dictates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback